This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
10/29/2020
Good morning, and welcome to the Genosha third quarter 2020 conference call. At this time, all participants are in listen-only mode. Following the formal remarks, we will open the call up for questions. Please be advised that today's call is being recorded at the company's request. At this time, I would like to turn the call over to Dan Ferry of LifeSci Advisors. Please proceed.
Thank you, operator, and good morning, everyone. Earlier today, we issued a press release that outlines the topics we plan to discuss today. This release is available at Genosha.com under the Investors tab. During the call today, Chip Clark, President and CEO, will provide a brief corporate update, and the company's Chief Financial Officer, Diantha Duvall, will review the financial results. After the prepared remarks, we will open up the call for Q&A, and Chip, Diantha, Tom Davis, Genosha's Chief Medical Officer, and Jessica Fleckner, Genosha's Chief Scientific Officer will then be available to answer your questions. Before we begin, I would like to remind everyone that statements made during this conference call relating to Genosha's expected future performance, future business prospects, or future events or plans may include forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All such forward-looking statements are intended to be subject to the safe harbor protection provided by the Reform Act. Actual outcomes and results could differ materially from those forecast due to the impact of many factors beyond the control of Genosha. Genosha expressly disclaims any duty to provide updates to its forward-looking statements whether as a result of new information, future events, or otherwise. Participants are directed to the risk factors set forth in Genosha's 2019 Annual Report on Form 10-K, and other periodic reports filed with the Securities and Exchange Commission. It is now my pleasure to pass the call over to Chip.
Thanks, Dan, and thank you all for joining us today. Genosha had an eventful third quarter, so let me jump right in. I'll start with Gen 11, our adoptive T-cell therapy designed to improve upon the limitations of TIL and TCRT therapies. We think of Gen 11 as a new third category of neoantigen T cell therapies. We call the category NPTs or neoantigen targeted peripheral T cells. In September, we announced that the FDA accepted our IND application for Gen 11, allowing us to initiate what we're calling the Titan study. a phase 1-2A trial to treat patients who have failed standard of care checkpoint inhibitor therapy. The trial will evaluate safety, T-cell proliferation and persistence, as well as clinical activity. Genosha plans to enroll up to 24 patients across several tumor types in two dose cohorts. In one, patients will receive multiple low doses of Gen11 with low-dose IL-2 and without lymphodepletion. In the other cohort, patients will receive a single Gen11 dose after lymphodepletion, followed by high-dose IL-2. We believe Gen11 may offer efficacy, accessibility, and cost advantages over TIL and TCRT therapy. The efficacy advantage stems from ATLAS, our neoantigen selection platform. Gen 11 includes CD8 and CD4 positive T cells only for the ATLAS-identified neoantigens driving antitumor responses and excludes T cells to protumor inhibigens. With these T cells, we will target up to 30 neoantigens per patient, ensuring a broad antitumor attack. there are two accessibility advantages. First, by using T-cells taken from peripheral blood, we avoid the challenges of extracting sufficient TILs from tumors, which may make some patients ineligible for TIL therapy. Second, Gen11 is HLA agnostic, meaning it should work in any patient regardless of their genetic makeup. The cost advantages also derive in part from our use of peripheral T-cells. Using such cells, we do not need the extra time or cost associated with the sterile tumor resection necessary for till extraction. Also, our planet T cell expansion process does not engineer the T cell and is robust and highly scalable. We, of course, aim to begin to demonstrate these benefits in the ongoing clinical trial. Next, I'll turn to Gen 9, our neoantigen vaccine program. In July, we presented initial clinical data for the first five patients from Part B of our ongoing Phase 1-2A clinical trial with Dr. Maura Gillison, a renowned professor of medicine at the MD Anderson Cancer Center and the lead investigator of the trial. Part B of the study is exploring the combination of Gen 9 and checkpoint inhibitor-based regimens in advanced solid tumors. Genosha shared follow-up clinical response and immunogenicity data from the same five patients at the European Society for Medical Oncology, or ESMO, Virtual Congress 2020. The incremental findings demonstrated tumor reductions or stable outcomes for all five patients, suggesting Gen 9 vaccination could be used in combination with CPI-based therapies to augment their effect. In addition, 100% of patients demonstrated immune responses to ATLAS-identified neoantigens. We look forward to reporting additional clinical and immunogenicity data from these and the remaining Part B patients during the 2020 Virtual Society for Immunotherapy of Cancer, or CITC, annual meeting from November 9th to 14th, as well as during a conference call on November 9th at 8.30 a.m., Details for this call will be provided in the coming days. Also at CITSE, we'll provide a detailed technical introduction to Gen 11 and share new insights on the utility of inhibogens as identified by Atlas. I'm now going to pass the call over to Diantha to summarize our financials from this quarter before opening the call up to questions. Diantha?
You're reading a preview of the GNCA Q3 2020 earnings call.
Free account.
